Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Petros Pharmaceuticals Inc (PTPI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: PTPI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -50.72% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.57M USD | Price to earnings Ratio - | 1Y Target Price 1 |
Price to earnings Ratio - | 1Y Target Price 1 | ||
Volume (30-day avg) 67163683 | Beta 2.03 | 52 Weeks Range 0.05 - 1.03 | Updated Date 04/1/2025 |
52 Weeks Range 0.05 - 1.03 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -117.52% | Operating Margin (TTM) -148.43% |
Management Effectiveness
Return on Assets (TTM) -28.49% | Return on Equity (TTM) -92.93% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5423488 | Price to Sales(TTM) 0.64 |
Enterprise Value 5423488 | Price to Sales(TTM) 0.64 | ||
Enterprise Value to Revenue 1.35 | Enterprise Value to EBITDA -0.15 | Shares Outstanding 29929700 | Shares Floating 8727861 |
Shares Outstanding 29929700 | Shares Floating 8727861 | ||
Percent Insiders 5.75 | Percent Institutions 8.68 |
Analyst Ratings
Rating 4 | Target Price 4 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Petros Pharmaceuticals Inc
Company Overview
History and Background
Petros Pharmaceuticals, Inc. (formerly known as Stealth BioTherapeutics Corp) focuses on identifying, developing, acquiring, and commercializing innovative therapeutics for men's health conditions. Founded in 2009 as a company in the mitochondrial dysfunction area and evolving toward a men's health focus, its trajectory has involved strategic acquisitions and licensing agreements.
Core Business Areas
- Men's Health Therapeutics: Develops and commercializes prescription medications for erectile dysfunction (ED) and other men's health conditions.
Leadership and Structure
The leadership team comprises executives with experience in the pharmaceutical and healthcare industries. The organizational structure typically includes departments for research and development, commercialization, finance, and operations.
Top Products and Market Share
Key Offerings
- STENDRA (avanafil): An oral phosphodiesterase 5 (PDE5) inhibitor for the treatment of erectile dysfunction. Market share is low and not accurately trackable compared to larger competitors. Competitors include Pfizer (Viagra), Eli Lilly (Cialis), and Bayer (Levitra).
Market Dynamics
Industry Overview
The men's health market is driven by aging populations, lifestyle factors, and growing awareness of available treatments. The ED market is highly competitive with generic versions of established drugs impacting pricing.
Positioning
Petros Pharmaceuticals is a smaller player in the men's health market, competing against larger pharmaceutical companies with greater resources and established brand recognition.
Total Addressable Market (TAM)
The global erectile dysfunction market is estimated to be in the billions of dollars. Petros's TAM is dependent on their ability to increase Stendra sales and introduce new products.
Upturn SWOT Analysis
Strengths
- Focus on men's health
- Established product (Stendra)
- Potential for new product development
Weaknesses
- Limited financial resources
- Small market share
- Strong competition
- High debt levels
Opportunities
- Partnerships and collaborations
- Expansion into new markets
- Development of innovative therapies
- Growing awareness of men's health issues
Threats
- Generic competition
- Pricing pressures
- Regulatory changes
- Economic downturn
Competitors and Market Share
Key Competitors
- PFE
- LLY
- BAYRY
Competitive Landscape
Petros faces intense competition from larger, more established pharmaceutical companies. Its advantages include a focused product portfolio, but its disadvantages include limited resources and brand recognition.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been inconsistent, marked by periods of revenue growth followed by declines due to market conditions and competition.
Future Projections: Future growth depends on successful commercialization efforts, new product launches, and strategic partnerships. Analyst projections are highly speculative.
Recent Initiatives: Recent initiatives have focused on expanding distribution channels and increasing marketing efforts for Stendra.
Summary
Petros Pharmaceuticals is a small player in the competitive men's health market. The company faces significant financial challenges and strong competition. Its success hinges on successful execution of marketing strategies and future opportunities that may present themselves. Securing partnerships and achieving profitability are critical.
Similar Companies
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
PFE
Pfizer Inc
PFE
Pfizer Inc
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. The data provided may not be entirely accurate or complete.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Petros Pharmaceuticals Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2020-12-02 | CEO - | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 21 | Website https://www.petrospharma.com |
Full time employees 21 | Website https://www.petrospharma.com | ||
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.